Replies to post #68 on Seneca Biopharma Inc fka SNCA

[locksflooring]

Volume Alert: Shares of stem cell company Neuralstem (NYSE AMEX: CUR) continued to surge on heavy volume, jumping 23% last week on three times average trade, likely helped by the announcement last month that its Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells was approved by the Institutional Review Board (IRB) at Emory University in Atlanta, GA. The trial, which was approved by the FDA in September, will take place at the Emory ALS Center, under the direction of Dr. Jonathan Glass M.D., Director of the Emory ALS Center, who will serve as the site Principal Investigator. Shares ended the week at $2.40, up 45 cents